Hemodynamic evaluation of hydralazine dosage in refractory heart failure

Milton Packer, Jose Mailer, Norma Medina, Richard Gorlin, Michael V. Herman

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Hemodynamic responses to different doses of hydralazine were evaluated in 18 patients with severe refractory resistant heart failure. There were no significant overall hemodynamic effects after 50 mg hydralazine. After 75 mg, CI increased slightly (+0.36 l/min/m2), with a 19% decrease in SVR. After 100 mg, there were substantial increases in CI (+0.60 1/min/m2) and decreases in SVR (↓31 %) changes which were greater than those after 75 mg, but the decrease in MAP with 100 mg (-6.6 mm Hg) was of the same order as that after 75 mg (-5.0 mm Hg). LVFP and SWI improved significantly only with 100-mg doses. Seven patients in whom 100 mg hydralazine induced no hemodynamic effects all responded to single doses of 150 to 200 mg. The duration of action of hydralazine was longer (p < 0.001) in patients with a CCr < 35 ml/min (14.3 ± 1.4 hr) than in patients with adequate renal function (7.9 ± 0.5 hr). Thus, the dose and dosing interval of hydralazine needed to induce hemodynamic improvement in patients with severe heart failure are variable and require individualization.

Original languageEnglish (US)
Pages (from-to)337-346
Number of pages10
JournalClinical pharmacology and therapeutics
Issue number3
StatePublished - Mar 1980

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Hemodynamic evaluation of hydralazine dosage in refractory heart failure'. Together they form a unique fingerprint.

Cite this